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EIGHTY TO NINETY PER CENT ofpatients
with lung cancer are potential candidates
for chemotherapy (Selawry, 1977). At
present a major limitation to the use of
chemotherapeutic agents is their lack of
specific anti-tumour activity. Doses re-
quired for adequate cancer treatment are
invariably accompanied by unwanted
systemic side effects, myelosuppression,
alopecia, neurotoxicity and damage to
gastrointestinal epithelium being among
the more prominent complications. The
concept of using anti-tumour antibodies
as carriers is an attractive one, in that the
potency of the cytotoxic drugs may be
combined with the specificity provided by
the antibodies. Since Ehrlich (1956) first
suggested this possibility, various drugs
have been linked to anti-tumour anti-
bodies. The multiplicity of methods used
for conjugation and the variety of test
systems investigated have been well
reviewed recently (Ghose & Blair, 1978;
Lee & Hwang, 1979; De Weger & Dullens,
1980; Rowland, 1981). We have previously
reported the ability of an anti-CEA Ig to
enhance the cytotoxicity of vincristine
in a 51Cr-release assay, using cultured
human lung-tumour cells (Johnson et al.,
1980). Inthis communicationwereportthe
cytotoxic effects of a vindesine-anti-CEA
Ig conjugate on cells from the same line,
using a terminal 3H-uridine uptake assay.
The sheep anti-CEA Ig was donated by
Dr A. R. Bradwell from the Immuno-
Diagnostics Research Laboratory, Uni-
versity of Birmingham. Its preparation
and characterization have previously been
described (Dykes et al., 1980). In these
experiments the initial protein concentra-
tion of the preparation was adjusted to
1 28 mg/ml with medium. Vindesine-Ig
conjugateswerepreparedatLillyResearch
Centre Ltd from desacetylvincaleucoblas-
tine acid hydrazide by a modification of
the procedure described for vindesine-
BSA (Conrad et al., 1979) and purified by
gel filtration. A solution of the anti-CEA
conjugate had a protein concentration of
1-28 mg/ml as assayed by the Lowry
method, and a drug concentration of
27-5 ,ug/ml, determined by difference
spectroscopy, giving a molar conjugation
ratio of 4 6. A conjugate with normal
sheep Ig had a protein concentration of
2-3 mg/ml and a drug concentration of
43 pg/ml, a molar ratio of 3'7. For com-
parison with the anti-CEA conjugate, this
and unconjugated vindesine were diluted
to an initial drug concentration of 27-5
,ug/ml in medium. Calu-6, the lung-tumour
line used in this study, was supplied by Dr
J0rgen Fogh, Sloan Kettering Institute,
New York. Calu-6 cells were originally
obtained from an anaplastic lung tumour
and maintained as a monolayer in Eagle's
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minimal essential medium, supplemented
with 15% foetal calf serum, non-essential
amino acids, L-glutamine and antibiotics.
We used a terminal labelling method
based on the ability of surviving cells to
incorporate 3H-uridine into their RNA-
precursor pools. This assay, described by
Smith & Nicklin (1979), has shown a direct
correlation between counts incorporated
and the number of viable cells, indicating
that it is a reliable method ofassessing cell
survival. Calu-6 cells in the exponential
phase of growth were trypsinized, washed
and resuspended in medium. One hundred
,l containing either 5x 103 or 104 cells
were dispensed into each well of a micro-
titre plate (Sterilin: M29ARTL) and
incubated at 37°C in a humidified atmos-
phere of air and 50o CO2. After 24 h,
doubling dilutions of drug, antibody or
conjugate were prepared and 50 y1 added
to the appropriate wells with 50 1l of
medium. Tests and medium-only controls
were performed in triplicate. After a
furtherincubation of72h, the supernatants
were discarded, the monolayers washed
x 3 with warm (37°C) phosphate-buffered
saline (PBS) and 100 1I of medium added
to each well. After recovery for 24 h, the
medium was again decanted and replen-
ished with 50 1ul of medium containing
1 HUCi 3H-uridine (Radiochemical Centre,
Amersham). After 3 h, when we have
shown that the transportation mechanisms
but not the RNA-precursor pools are still
saturated by uridine, the medium was
removed, the cells washed with PBS, and
150 1l of ice-cold 5%o trichloracetic acid
added to each well for 20 min. One hundred
and twenty-five yu of this was then
removed for scintillation counting.
The surviving fraction was calculated
as:
Mean radioactive count (ct/min)
in test wells 100%
Mean radioactive count (ct/mini) 0
in medium control wells
The interrupted line in Fig. I shows the
dose-response curve for vindesine in this
system. The anti-CEA immunoglobulin on
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Fia. 1. Thle effect of vindesine (---); anti-
CEA Ig (.); drug and antibody mixed but
not linked (- ) and the conjugate (-)
on the surviving fraction of a lung tumour
cell line, Calu-6 (±s.d.).
its own had a low cytotoxicity, and when
added to the drug at the relevant con-
centrations the effect closely paralleled
that of drug alone. However, with the
vindesine-anti-CEA conjugate there was
a marked dose-dependent decrease in sur-
viving fraction.
Fig. 2 shows the results of a second
experiment, performed to compare the
effects ofthe drug conjugated to anti-CEA
Ig and to the normal sheep Ig using 104
cells per well. Whereas the conjugate of
vindesine with normal sheep Ig had little
effect on cell survival, the anti-CEA
conjugate produced a dose-dependent de-
crease in surviving fraction. In a 2-stage
immunoperoxidase test, the anti-CEA Ig
localized on Calu-6 cells and on CEA-
secreting colonic adenocarcinoma cells,
both before and after conjugation. Simi-
larly in a competitive-inhibition test with
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FIG. 2.- A comparison of the effect of two
vindesine-Ig conjugates, anti-CEA
an(l normal slheep IgG (---), on the surviving
fraction of tutmour cells ( ± s.d.).
CEA, using an enzyme-linked immuno-
absorbent assay (ELISA), the anti-CEA
Ig showed abinding to CEAwith, however,
some apparent loss ofreactivity.
Four conclusions may be drawn from
the results presented here: first, that the
drug-antibody conjugate is more potent
in this in vitro system than the correspond-
ing drug alone; second, that the conjugate
of vindesine and anti-CEA Ig retains drug
action and antibody activity; third, that
the specificity of the carrier is of impor-
tance; and, fourth, that simple mixing of
drug and antibody does not amplify the
drug effect.
The anti-CEA Ig used here has already
been shown to localize on Calu-6 cells in
immunofluorescence and immunoperoxi-
dase tests (Johnson et al., 1980). Further-
more, its ability to localize on a variety of
primary and secondary human tumours
in vivo has been convincingly demon-
strated (Dykes et al., 1980). The immuno-
peroxidase and ELISA results demon-
strate that the anti-CEA Ig after conjuga-
tion retains its ability to recognize CEA
determinants. However, preliminary evi-
dence with these tests suggests that there
is a loss of anti-CEA activity with storage
at 4°C. This may explain the difference in
surviving fraction of the anti-CEA conju-
gate seen in Fig. 1 (31 days after conjuga-
tion) and Fig. 2 (52 days).
Although CEA is not tumour-specific, its
concentration may be greatly increased in
gastro-intestinal, lung and other malig-
nancies. This difference has been exploited
by investigators who have reported in
vivo tumour localization using radio-
labelled antibodies against CEA, in some
cases despite high circulating levels of the
antigen (Goldenberg et al., 1978; Mach
et al., 1980). Antibodies to CEA may,
therefore, provide useful carriers for cyto-
toxic compounds, thereby achieving a
selective accumulation of the drug at its
desired site of action. The specificity and
potency of such therapy may be further
improved by using monoclonal antibodies
from a hybridoma source. In this context,
xenogeneic (Ghose et al., 1975; Newman
et al., 1977; Goldenberg et al., 1978; Mach
et al., 1980) and monoclonal (Nadler et al.,
1980) antibodies have already been ad-
ministered safely to cancer patients.
In the system reported here it would
appear that the potency ofa vinca alkaloid
is remarkably increased by the ability of
the antibody to deliver it to tumour cells.
We are currently extending our investiga-
tions into the stability, affinity and speci-
ficity ofthevindesine-anti-CEA conjugate,
with a view to its clinical applications in
the treatment of cancer.
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